for "nightly business report," i'm meg terrell. >>> a weak forecast sent shares of eli lily down and that's where we begin market focus. the drug maker struggled because of competition from generics and expecting 2015 earnings and revenue to be shy of wall street's estimates. still, the company is betting on a new pipeline of treatment for illnesses like diabetes and cancer. the shares fell slightly to $69.23. monsanto saw earnings fall. steeper than expected. blamed lower corn seed sales for the slump but managed to beat on the top and bottom lines, that sent shares to $117.21. super value reported better than expected results for third quarter. its profits more than doubled as the super market posted sales growth in all three business segments segments. shares flat closing at $9.19. >> dr. pepper snapple, make do it yourself soda. keurig expected to come out with a cold carbonated drink maker in the fall and coca-cola is on board. keurig shares popped 4.5% to $123.02. and up to 72.52, excuse me. sirius said it would beat its 2014 revenue forecast as it added more subscribers than f

for "nightly business report," i'm meg terrell. >> one of the most watched experimental drugs, and that is where we begin tonight's market focus. the therapy showed promise of being able to repair optic nerve damage and the hints that could help those suffering from multiple sclerosis. some results show it lacked clarity. the wholesale retailer costco saw its same store sales better in november. with the positive results from the holiday shopping beardperiod rose to $125.56. family dollar earnings report out. the fiscal first quarter profit weaker than expected as it stepped up discounting and more sales of lower mor gin items. shares fell to $78.51. >> strong sales of caakoe corona fell. star board value renewed pressure on yahoo to buy aol sending shares of both companies higher. in a letter to yahoo's ceo, chief repeated it should improvement the profits. yahoo rose by more than 3%. aol up by 7.5%. shares of ford rose up after the auto maker hiked quarterly dividend by 40%. the payout 15 cents a share and payable at the end of the month. lifted the shares up 2 pbt.5% to $15.42. >>> t

i'm meg terrell in san francisco. >>> college football is getting even bigger. but not necessary live for the athletes. is it time for them to be compensated financially. >>> the republican controlled senate is taking up legislation to resume construction of the controversial keystone pipeline setting up a showdown with president obama after he vowed to veto the bill if it passes. the candidates of texas oil pipeline bill was approved in the house la >>> the u.s. military central command had its twitter and youtube accounts hacked for a short time today. but people claiming to work with the islamic state militants. the twitter site even posted a thread that said quote, american soldiers we are coming watch your back end quote. no classified material was exposed, and pentagon officials which quickly suspended the site called the breach embarrassing but not a threat. >>> the unsettling cyber attack on the u.s. military comes on the same day president obama pushed for new measures to protect the nation's computer networks from hackers. >> this is a direct threat to

meg terrelle looks and bertha coombs tackles health care. >> reporter: washington looms large over health care in 2015 with congress and the supreme court set to revisit health reform. repeal and replace obamacare? it won't happen. the republican majority and congress will revise parts of the health reform law, likely eliminating the 2.3% tax on medical advices. but kick in for employees 40 hours a week. supreme court won't do obamacare either. there will be dram in king vs. burwell challenging subsidies on healthcare.gov. plans unstated exchanges. ruling against the administration could gut the enrollment. expect to find middle ground between the spirit and the letter of the law. >> in the big push towards consumer related health care established players and new entrants are going to push technology at us making 2015 the year of the wearable health gadget. even apple's watch will struggle to dominate in a crowded market. health i.p. infrastructure players will be the real winners with increasing demand on data. >> if you wanted growth in 2015 you almost had to be in biotech and pharma. s

. >> our own meg terrell is there. she joins us with the ceo of biogen. meg?and bill thank you so much. i'm joined by the ceo of biogen. it's been a very busy cycle for you. let's start with your ms drug it was the pipeline data that just read out. tell us about the way the market should respond to that. it was a little bit of a mixed reaction. >> we're very encouraged by the data. it was a trial intended to determine whether or not the compound had the ability to induce remile nation and we believe it did demonstrate that. >> that's actually repairing the nerve damage you see in multiple sclerosis. >> in to repair the nerve damage. we did not have an impact on the disease process in that area so some people have had questions about that but we don't believe those issues are relevant to ms. the most relevant measure for ms is whether or not we can induce remylenation. >> so there's potential to start reversing some of the damage. >> that would be the hope. we have a trial going on in multiple sclerosis going on now. i would say the results of this trial certai

also josh julia boorstin and meg terrell all watching these companies, guys. back over to you. >> i'm hydrating. thanks, dom. appreciate it. dominic chu with 12 minutes to go into the close. the dow is off, look at this heading back towards the lows. we were down a lot more but we're currently minus 270 points. just hanging onto the 17,400 mark on the dow. >> we'll take you to the final minutes of this rough day. the heat map tells the story. a lot of red, not much green. we'll be right back. in my world, wall isn't a street. return on investment isn't the only return i'm looking forward to. for some every dollar is earned with sweat, sacrifice, courage. which is why usaa is honored to help our members with everything from investing for retirement to saving for college. our commitment to current and former military members and their families is without equal. start investing with as little as fifty dollars. >>> eight minneapolis left inutes left in the trading session. the dow heading lower. art cash ynkashcashin just came by. it's minuscule in financial terms

meg terrell has the latest news. hi meg. >> hi tyler. that's right.sident obama unveiled his precision medicine initiative today to a room packed with researchers. what it will involve is a $215 million investment in this initiative. it will initially start to focus on cancer. better understanding the genetic drivers of the diseases that make up cancer. also, just better understanding each person's health. to that end they'll be compiling a national gate daita base on more than a million volunteers in the united states. compiling genomic information, information for medical records, information on lifestyle. >> it takes long periods of time. particularly biological science that is depend on biological timelines. i think this activision and this foundation that can be built here by the president's efforts here, by companies like us can really contribute to making a difference. they also included vertex and illumina and -- we also spoke with tony kohl's the cancer company that was sold to amjen for $10 million. he called this unprecedented and historica

agios jumped again on the strength of an interview with meg terrell. regenron did it again. bristol-myers announced a break that it had to break up the study because it just wasn't fair to deny the drug to those taking the placebo. it was hard to keep the entire market down. when the first big decline in oil the market does get hammered. it tends to go down in oil and the rest of the market consolidates and causes so much of the market to stabilize that we are back to depending on the new set of earnings and whether we will rally or fall. good news later on in the show. alcoa good but it is the day to day. tech, oil and retail took a stand. restaurants and bio tech couldn't save us but it wasn't for lack of trying. how about sherry in new york? >> hello jim. i must tell you i am a huge fan. i just adore you, love your positive energy enthusiasm and the sanity you bring to this manic market. >> you have a british accent too. >> caller: i hope i am not too cheeky when i say i look forward to you every night, jim. >> not cheeky at all. very reassuring. >> caller: i am calling a

lifting the biotech sector and let's bring in meg terrell. why is it up? >> it's all about drug pricing. remember last month when the sector took a hit when gilead's two hepatitis-c drugs were going to be excluded and took a hit on the stock and the right of the industries and people worried that maybe other pharmacy benefits managers excuse them from their plans and cvs caremark. today we have news that cvs is going to include the drugs of gilead and exclude the competitor's. and so, it's really interesting to see that, you know, gilead is maybe more expensive treatment and folks speculate they're giving a big discount to get the exclusive price. >> maybe $1,000 a pill, right? unfortunately we don't have time. >> that's okay. >> that's the controversy. thank you. >> thank you. >> that's because the stock market is doing what it's doing and let's get back to the markets. dow dropping 345. gordon, is there any one thing that is causing this decline today? >> not one thing. i would just say it's a rather sobering way to come back from a new year's vacation.

meg terrell hoping to find more answers to that question.oins from yous jp morgan health care conference in san francisco with the ceo of erexogen, that i understand is one of the newest players in the obesity game. >> thank you so much. we're joined by the ceo of erexogen. >> we have the confidence we have in the launch, and perhaps why we're producing the early successful ruts is it's a differentiated launch. got a really strong partner. they've got rights to contrave in north america, and they came out with a launch that i think is what it takes critical mass primary care. you have to have a great product and xrenszive and integrated marketing plan and the resources to back it up. it could be a great solution for a large number of patients. >> some of the challenges of the previous drugs that have entered the market is paying for them. getting reimbursement for them. how is that doing for you guys? >> it's gl well, but part of the comprehensive launch plan is getting the price right, and our goal was for the majority of americans who want

meg terrell is live at the jp morgan health care conference in san francisco with the chairman and ceoiad. over to you, meg. >> thank you so much. joining me now is dr. harvey berger where are thank you for joining us. >> thanks very much, meg. >> just mentioning your stock price has been rising. you guys gave some outlooks for profitability in 2018. starting some new trials to try to expand your approved cancer drug. it had been pulled off the market, as we know. tell us about the progress. >> commercially we've had a really good year. we've really made progress in the u.s. as well as in europe. most importantly, as we look to the future three major new trials. the most important one of which is a head-to-head comparison with a market leader which is nolocnid. second line in the pashgts who failed clevec. we're also going to the -- >> pipeline as elt 113. >> or 113. that's really part of the next step in terms of building out our overall business. >>> a real focus on profitability in three years, and over $400 million in product revenues as we look to three years from now. >> now, one

i'm sarah filling in today for alicia lee, joined by meg terrell, and stephanie ling, portfolio managerf jim cramer's charitable trust. let's kick it off with our score card. of the 19% of s&p 500 firms reporting so far, 72% have actually beaten estimates. 9% met estimates, and 19% coming in below estimates. ahead of us tomorrow pfizer reporting before the bell, meg. everyone is talking about m&a when it comes to pfizer. >> in a way the fourth quarter really isn't such a big deal, but let's start with what people are looking for. etf's down about 5% from last year. revenue 12.9 billion. down about 4%. a lot of it might be impacted by fx. it's a theme we've been seeing. the stronger dollar affecting these companies. pfizer gets 61% of its revenues from overseas. that could be the estimate of 4%. revenue head wind for the fourth quarter for pfizer, because of fx. a few other things afrting pfizer's loss of excluesivity on some of the top selling drugs. some of those include vyinga, lipitor, celebrex, some of those worldwide. those have been affecting revenue. we'll see more. the antibioti

the ceo of aigos pharmaceutical joining us now along with meg terrell, our own biotech reporter. guess, meg, i'm not going to put words in your mouth or questions, but just ask the doctor. hey, you gave up 250% over 12 months, what are you going to do for us today. >> i know, brian. you were fantastic bringing on the doctor last year. now he's here again. >> always great to be here. >> let's start off with brian's question. you had a tremendous 2014. can you do it again? >> so 2014 clearly was an exciting year for us, as we brought three novel medicines into clinical trials, two in cancer and one in a rare genetic disease. and in all three, we've shown some really, really promising early data. we think 2015 will be as exciting, hopefully, not only for us, but for patients as 2014. because two of our cancer programs are moving into the registration phase. so for global regulatory approval, we'll start those trials in 2015, early 2016. and the third molecule will start the phase ii trial. so we think 2015 could be as exciting for us as 2014 and our research continues to come up behi

it's underway in san francisco and that's where we find a very business meg terrell. ins us now live. hi, meg. >> hi sue. we're joined by bluebird ceo, nick leshi. thanks for being here. >> thank you for having me. >> you've had a huge 2014 just seeing your stock rocket. now, maybe it would be helpful for our viewers if you could explain what the excitement is about. we're talking about gene therapy, essentially trying to cure diseases. >> that's right, megan. i think that's the key point, that we're cure. that's a big word. it's almost setting dangerously high expectations, but that's always been the promise of gene therapy. the whole concept of gene therapy is that you have a gene that's broken and the technology that we use is to acquire the appropriate cells in the body and then give you back functioning copies of that gene. and so you're sort of treating the disease at its heart. the notion there is that if you can do that do it one time you can potential liqueur really deadly diseases terrible diseases. and that is the data that you just referenced. we had four p

meg terrell is live at the white house. give us more about this? >> that's right.heard earlier this week about the mysterious invitations sent out to drugmakers we got the details today at the white house. several drugmakers and researchers from industry and academia met at the white house where the president unveiled this precision medicine initiative. he's going to be funding it with $215 million. he's aiming to give to the nih, national cancer institute and the fda and others and focusing initially on cancer, trying to better understand the genetic drivers of cancer. another part of this initiative is to compile a database of health information on more than a million americans. now that will include genetic information but also information about lifestyle from their medical records and also through personal health devices and the idea here is collaboration with the people volunteering to be involved in this with industry, with the research community, and, of course, the companies here say a lot about what they're aiming to do. alumna one of the biggest makers of

. >> let's send it to meg terrell at headquarters. >> looking at gilead, giving the preferred statusthe drugs. its hepatitis c drugs. a turnaround from when we saw gilead excluded from express scripts plan on the drugs that have been controversial because of their price tags seeing another pharmacy manager, cvs, saying it will exclusively cover gilead's sovaldi status. they say the competing hepatitis c drug will only be available through medical exception or prior authorization, driving up gilead shares, driving down abbvie's now. >> a lot of moves in that space. when we come back, check out the price of oil, watching it all morning, continuing to slip as crude moves closer to the key $50 a barrel mark at 50.25. we will get rick santelli's take when we come back on "squawk alley." . >>> welcome back to "squawk alley." rick santelli with monday's rendition of the santelli exchange. i was going to talk about interest rates and we'll get to it, but i was led somewhere else. robert mcnamee on talking about the dark side of some of these synthetic financial products that have caused hous

meg terrell has that story. this is exciting news. >> yeah it's a really new thing. so we're just hearing this news out of the fda yesterday which could affect some of the most expensive medicines for cancer which are also some of the biggest moneymakers in the drug industry. we're all familiar with drugs like lipitor. often it opens up the market to cheaper generic copies. there hasn't been a path to market for generic copies in the united states. that's changing. yesterday an fda advisory panel recommended approval of what would be the first biologic drug in the u.s. the industry calls them biosimilars because they're not completely identical. it's called ep-2006 made by novartis. it would be a lower cost version of neupogen used to support the immune system when patients are taking chemotherapy. that and a similar drug brought in almost $6 billion in 2013 for am amgen. don't worry too much about amgen. it's getting into biosimilars itself. >> i read a little bit about it in the past day or two, a potential breakthrough in the search for antibiotics, an area that's

bricking here is meg terrell. meg? >> bill, thank you so much. we're joined by vertex's ceo dr. jeff leiden. >> good to be here. >> you put out some information on sunday night explaining just the future of expanding your cystic fibrosis drugs to more cf patients. tell us about how many patients you can treat with these drugs. >> we're really on a journey with cf patients. today our medicines are approved for 3,000 patients around the world out of a total of 75,000. what we're really excited about is we expect to get approval for our next combination of medicines and that will allow us to expand from 3,000 to as many as 25,000 over the next year. >> big question people have for you and you don't have approval yet but upon approval which i think is expected is pricing. and with orphan drugs you can often price $300,000. i think some people expect that the combination you have that could potentially come late they are year could be less than that. can you give us any guidguidance? >> it's way too early to talk about pricing. we haven't even seen the label we're going to get or the

meg terrell talking about good trials on these drugs, ms and optic nerve and the like. >> celgene saying one of their favorites. isis this morning, this is the good isis not the bad isis preannounces they've got more cash than people thought. they want biotech. biotech got too hot. got to be careful. >> we are heading into the thick of conference season. >> there will be good news next week. you might get a chance to buy them again. >> with all that dow is up 181. we bark to s&p 2045. let's get to bob pisani on the floor. >> another nice rally. all ten sectors in the up. being led by health care. europe on the up side. buying yields quieter today. oil on the downside a few pennies here. more positive environment for equities. last night around 9:00 did you see this? s&p futures moved 15 handles. everybody seems to agree charles evans who is the head of the chicago federal reserve gave a speech saying it would be a catastrophe, his words, to raise rates. evans is an uber dove. he is now a voting member of the fomc. most traders seem to agree that was the overriding factor in the move to t